PUNE, India, August 28, 2015 /PRNewswire/ --
According to a new market research report "Cancer
Biomarker Market by Tumor (Breast, Lung, Prostate) Type (Protein
& Genetic Biomarkers) Profiling Technology (Proteomics,
Genomics, Imaging, Immunoassay) Application (Diagnostic, Drug
Discovery, Prognostic) & Geography - Global Forecast to
2020", published by MarketsandMarkets, The Cancer
Biomarkers Market is expected to reach around 17,689.0 Million USD by 2020 at a CAGR of 13.9%
during the forecast period of 2015 to 2020.
Browse 191 Tables and 38 Figures spread through 174
Pages and in-depth TOC on "Cancer Biomarker
Market"
http://www.marketsandmarkets.com/Market-Reports/oncology-biomarkers-202.html
Early buyers will receive 10% customization on this
report.
The Cancer Biomarkers Market is valued at USD 9,227.5 Million in 2015, at USD 17,689.0 Million by 2020 and is expected to
grow at a CAGR of 13.9% during the forecast period of 2015 to
2020.
Ask for PDF Brochure:
http://www.marketsandmarkets.com/pdfdownload.asp?id=202
Cancer biomarkers are molecules secreted by a tumor or a
specific response of the body to the presence of cancer. These are
also referred as substance or processes which are indicative of the
presence of cancer in the human body, which enhances the cancer
detection and facilitate high speed, non-invasive diagnosis using
genomics and proteomics based tools. The cancer biomarkers are used
for drug discovery and development, diagnostics, personalized
medicine, and therapeutics.
In this report, the cancer biomarkers market is segmented on the
basis of type of biomarkers, tumor type, profiling technologies,
applications, and region. Based on biomarker type, the market is
segmented into protein biomarkers, genetic biomarkers, and others
which include viral, cell, and carbohydrate biomarkers. Based on
tumor type, the market is segmented into breast cancer, lung
cancer, colorectal cancer, prostate cancer, cervical cancer, and
other type of cancers such as Gastrointestinal Stromal Tumors
(GIST), lung, ovarian, bladder, pancreatic, kidney, melanoma, and
leukemia cancers. Based on profiling technologies, the market is
segmented into omics technologies, imaging technologies,
immunoassays, cytogenetics, and bioinformatics. Based on
applications, the market is segmented into diagnostics, drug
discovery and development, prognostics, risk assessment, and others
which include surrogate endpoints, recurrence, personalized
medicine, and therapeutics. This report also discusses key market
drivers, restraints, opportunities, and challenges for this market
and its submarkets. The global cancer biomarkers market is expected
to reach USD 17,689.0 million by
2020, at a CAGR of 13.9% from 2015 to 2020.
The diagnostics segment is the largest application of cancer
biomarkers which includes tests that access the biological makeup
of individuals at the molecular level to determine the individual's
predisposition to a particular disease or condition and diagnose
it. With the introduction of new technologies and applications,
this is one of the most rapidly advancing areas of research and
medicine. The rising prevalence of cancer; increasing demand
for advanced diagnostics tests; increased awareness and acceptance
of diagnostics tests; advancement in technologies; and the need for
early-stage cancer diagnosis further propels the growth of this
market.
In 2014, North America
accounted for the largest share of the cancer biomarkers market,
followed by Europe, Asia-Pacific, and RoW. The major shares of
North America and Europe are primarily attributed to rising
prevalence of cancer, faster adoption of advanced technologies like
advanced high throughput technologies, increasing research studies
on discovery and development of novel biomarkers, presence of large
number of pharmaceutical companies, rising funding and investment
from public and private organizations, presence of key players in
these regions, and rising applications of biomarkers in patient
stratification and drug development process. The future growth of
the cancer biomarkers market will be driven by the Asia-Pacific region, owing to the rising
incidence of cancer in this region, increasing use of biomarker
tests for diagnosis purposes, expansions of major pharmaceutical
companies in emerging Asian economies, and government support to
research institutes and universities. However, poorly suited
regulatory and reimbursement systems for biomarker tests and
requirement of high capital investments for biomarker discovery and
development are expected to restrain the growth of this market
during the forecast period.
The prominent players in the Cancer Biomarkers Market are Abbott
Laboratories (U.S.), Affymetrix Inc. (U.S.), Roche Diagnostics Ltd.
(Switzerland), Illumina, Inc.
(U.S.), Qiagen N.V. (Netherlands),
Agilent Technologies (U.S.), Thermo Fisher Scientific Inc.
(U.S.), Merck & Co. Inc. (U.S.), Becton
Dickinson and Company (U.S.), and Hologic Inc. (U.S.).
Browse Related
Reports:
Cancer Diagnostics Market by Technology (ELISA, ELFA,
PCR, NGS, Immunohistochemistry, Microarray, Imaging (MRI, CT, PET,
Ultrasound, Mammography), Biopsy), Application (Breast Cancer, Lung
Cancer, Colorectal Cancer, Melanoma) - Forecast to 2020
http://www.marketsandmarkets.com/Market-Reports/cancer-diagnostics-market-186559121.html
Biomarkers Market by Product (Consumables, Services),
Type (Predictive, Pharmacodynamic, Safety), Application
(Diagnostics, Drug Discovery, Personalized Medicine) & by
Disease Indication (Cardiovascular, Immunological) - Global
Forecast to 2020
http://www.marketsandmarkets.com/Market-Reports/biomarkers-advanced-technologies-and-global-market-43.html
About MarketsandMarkets
MarketsandMarkets is world's No. 2 firm in terms of annually
published premium market research reports. Serving 1700 global
fortune enterprises with more than 1200 premium studies in a year,
M&M is catering to multitude of clients across 8 different
industrial verticals. We specialize in consulting assignments and
business research across high growth markets, cutting edge
technologies and newer applications. Our 850 fulltime analyst and
SMEs at MarketsandMarkets are tracking global high growth markets
following the "Growth Engagement Model - GEM". The GEM aims at
proactive collaboration with the clients to identify new
opportunities, identify most important customers, write "Attack,
avoid and defend" strategies, identify sources of incremental
revenues for both the company and its competitors.
M&M's flagship competitive intelligence and market research
platform, "RT" connects over 200,000 markets and entire value
chains for deeper understanding of the unmet insights along with
market sizing and forecasts of niche markets. The new included
chapters on Methodology and Benchmarking presented with high
quality analytical infographics in our reports gives complete
visibility of how the numbers have been arrived and defend the
accuracy of the numbers.
We at MarketsandMarkets are inspired to help our clients grow by
providing apt business insight with our huge market intelligence
repository.
Contact:
Mr. Rohan
Markets and Markets
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune, Maharashtra 411013,
India
1-888-600-6441
Email: sales@marketsandmarkets.com
Visit MarketsandMarkets Blog @
http://mnmblog.org/market-research/healthcare/medical-devices
Connect with us on LinkedIn
@ http://www.linkedin.com/company/marketsandmarkets